TBC Astellas Pharma Australia Pty Ltd
Product name
TBC
Accepted date
May-2024
Active ingredients
avacincaptad pegol
Proposed indication
For the treatment of adults with Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD).
Application type
A (new medicine)
Publication date
May-2024